1Gustafsson L, PontenJ, Zack M, et al. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997;8:755-63.
2Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
3Monk BJ, Tewari KS, Koh WJ. Mulumodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J Clin Onco12007;25:2952-65.
4Tewari KS. Expert panel: patients with metastatic/ recurrent cervical cancer should be treated with cisplatin plus paclitaxel. Clin Ovarian Cancer 2011;4:90-3.
5Monk BJ, Sill MW, McMeekin DS, et al. Phase HI trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009;27:4649-55.
6Tewari KS. A critical need for reappraisal of therapeutic options for women with metastatic and recurrent cervical carcinoma: commentary on Gynecologic Oncology Group protocol 204. Am J Hematol Oncol 2010;9:31-4.
7Tewari KS, Monk BJ. The rationale for the use of non- platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. Clin Adv Hematol Oncol 2010;8:108-15.
8Tewari KS, Monk BJ. Gynecologic oncology group trials of chemotherapy for metastatic and recurrent cervical cancer. Curr Oncol Rep 2005;7:419-34.
9Bonomi P, BlessingJA, Stehman FB, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol 1985;3:1079-85.
10ThigpenJT, BlessingJA, DiSaia PJ, et al. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1989;32:198-202.
